AI-assisted colonoscopy linked to higher adenoma detection in limited preprint data

A preprint circulated this week from an Indian clinical group reports a sizeable jump in polyp detection rates after an artificial-intelligence tool was folded into routine colonoscopy work. According to ThePrint, doctors identified at least one adenoma — the kind of growth that can become cancerous if left in place — in 28.4 per cent of colonoscopies in the three months before the tool was introduced. In the three months after, the adenoma detection rate rose. The figure that has begun circulating in medical channels is the kind of headline number that tends to travel faster than the methodology behind it.

The result, if it holds, is consistent with a broader pattern in medical imaging: AI assistance tends to push detection rates up because the model rarely misses what a trained eye might briefly overlook. But a three-month before-and-after comparison at a single site is a thin foundation on which to build a national screening policy. The right way to read the preprint is as a signal that warrants a properly powered trial, not as proof that AI colonoscopy is ready for routine deployment across India's district hospitals.

What the preprint says, and what it does not

The comparison is structured as a classic before-after audit: the same clinicians, the same patient population, the same endoscopy suite, with one variable changed — the AI overlay. Detection rates rose from a 28.4 per cent baseline. ThePrint's reporting, drawn from a Telegram-circulated summary of the preprint, does not specify the post-intervention figure, the size of the patient cohort, the name of the AI vendor, or whether the endoscopists were blinded to the tool's output during the procedure. Each of those omissions matters.

A detection-rate lift on the order of several percentage points is plausible. Published randomised data from Europe and East Asia has previously suggested similar magnitudes of improvement when AI is used to flag flat or subtle lesions. But those studies generally used per-patient randomisation, formal adenoma confirmation by histopathology, and multi-site recruitment. A single-centre, time-segmented audit cannot distinguish between a real algorithmic effect, a Hawthorne-style lift in clinician attention, and the regression-to-the-mean that often accompanies the first months of a quality-improvement programme.

The Indian clinical context

Colorectal cancer incidence in India has been climbing as diets urbanise and screening infrastructure spreads beyond the metros. Detection rates in routine practice remain well below those reported in Western screening programmes, partly because colonoscopy volume per capita is lower and partly because the average endoscopist sees a different lesion mix — more flat polyps in the right colon, fewer classic pedunculated growths that are easier to spot.

An AI overlay that flattens that detection gap would have real public-health value. India does not have the radiologist-and-gastroenterologist density that high-income systems rely on, and a tool that lifts a junior endoscopist's adenoma hit rate closer to a senior colleague's is doing more than adding convenience — it is, in principle, substituting for years of training. The preprint sits inside a broader Indian push into applied clinical AI: tuberculosis screening on chest X-rays, diabetic retinopathy grading on fundus photographs, and cervical cytology triage have all been the subject of large deployment pilots in the past three years.

The structural read

The pattern is familiar. A clinical task with a known performance gap — in this case, missed adenomas during colonoscopy — attracts a wave of vendor-supplied AI tools that promise to close it. Early evaluations tend to come from the vendors themselves or from the enthusiastic early adopters who selected the tool. Publication bias runs strongly positive: papers that show no improvement rarely make it into preprint circulation. Regulators, pressed to keep pace, approve on the basis of locked-version retrospective benchmarks rather than live deployment data. By the time independent confirmatory trials are funded and run, the first generation of the tool has already been sold to hundreds of hospitals.

What is missing from the current picture is the post-market surveillance architecture that would catch failure modes early. If an AI colonoscopy overlay systematically misses a particular subtype of lesion — flat serrated adenomas in the right colon, for instance, the very lesions most likely to be missed by a Western-trained model — the harm will show up first as interval cancers in patients screened in 2026 and diagnosed in 2028 or 2029. By then the tool will be embedded in procurement contracts. The structural question is not whether AI helps colonoscopy. It almost certainly does, in many settings. The question is who is independently auditing the deployed models, on what patient populations, and with what consequences for vendors whose products drift.

What we verified, and what we could not

The preprint's existence and the 28.4 per cent pre-intervention adenoma detection rate are reported by ThePrint and traceable to a Telegram-circulated summary. The post-intervention figure was not in the source material available to this publication. The name of the hospital or clinical group, the AI vendor, the patient cohort size, the endoscopist roster, and the blinding protocol are not specified in the materials available. Whether the result has been peer-reviewed, deposited in a recognised preprint server, or replicated by an independent group could not be confirmed from the available reporting.

For an independent read of the claim, the next steps are: locate the preprint itself, identify the AI tool by name and version, examine the per-endoscopist stratified results, and check whether any of the authors declare conflicts of interest with the vendor. Until those moves are made, the right editorial stance is measured: a single-site before-after audit is a reason to design a trial, not a reason to change procurement.

Stakes

If the result generalises, the beneficiaries are large. Patients gain earlier detection of pre-cancerous lesions. Junior endoscopists close part of the experience gap. Public-health systems get more cancer prevention per endoscopy suite. If the result does not generalise — if the lift was driven by clinician enthusiasm, by a favourable patient mix in the post-period, or by a tool that quietly degrades on a different patient population — the cost is paid in interval cancers that surface years later, in patients who were screened in good faith.

The honest position is to wait for the confirmatory trial, watch for independent replication, and resist the gravitational pull of a clean before-after number. AI colonoscopy is plausibly useful. The evidence currently in circulation is plausibly suggestive. Conflating the two is the most common failure mode in clinical AI reporting, and the one worth avoiding here.

This article traces a single preprint circulated via Indian outlets and Telegram research channels. Where the source material did not specify a figure, a name, or a methodology, this publication has said so rather than fill the gap. Monexus treats clinical AI claims the same way it treats claims in any other sector: the first reading is sceptical, the second is patient, and the byline is earned by what the sources can carry.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://t.me/thePrintIndia
• https://t.me/thePrintIndia
• https://en.wikipedia.org/wiki/Colonoscopy
• https://en.wikipedia.org/wiki/Adenoma
• https://en.wikipedia.org/wiki/Colorectal_cancer
• https://en.wikipedia.org/wiki/Computer-aided_detection